Luthardt T
Dtsch Med Wochenschr. 1980 Jul 11;105(28):993-7. doi: 10.1055/s-2008-1070798.
Seven patients received a total of 23 infusions of a polyvalent largely monomeric and intravenously applicable immunoglobulin preparation (Sandoglobulin). Among them are two with congenital antibody deficiency syndrome. One of them, who has agammaglobulinaemia type Bruton, is still receiving 9 g Sandoglobulin every three months. During the now 40-week period of observation the IgG serum level has remained adequately high, and the patient has had no infection; half-life of the Sandoglobulin is 32.4 days. In the other patient, with recently diagnosed hyper-IgM syndrome, 6 g Sandoglobulin were administered every month or every second month. During an observation period of 44 weeks he had not further infections. The initially much increased IgM serum level (16 g/l) slowly but definitely fell during substitution to 9 g/l at the end of the observation; half-life of Sandoglobulin is 34.1 days. All 23 Sandoglobulin infusions were given without side-effects.